BAY 1902607: Single dose escalation, safety and tolerability, pharmacokinetics, bioavailability, food effect
This study is a first-in-man study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1902607 using a placebo controlled, randomized, single center design. In addition the influence of food on the pharmacokinetics of BAY1902607 and the bioavailability between different pharmaceutical formulations will be investigated
- Healthy male subjects. - Age: 18 to 45 years (inclusive) . - Body mass index (BMI) : ≥18 and ≤30 kg/m^2. - Race: White.
- Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance. - Relevant diseases within the 4 weeks before the first drug administration. - Febrile illness within the week before the first taste test is conducted.
CRS Clinical Research Services Berlin GmbH
Berlin, Germany, 13353
E-mail: [email protected]
Phone: (+) 1-888-8422937
Randomized, placebo-controlled, double-blind, parallel-group study to investigate the safety, tolerability and pharmacokinetics of increasing single oral doses of BAY1902607 including the relative bioavailability between different pharmaceutical formulations and the effect of food on the pharmacokinetics of BAY1902607 in healthy men